id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-035024-kx9jfssi	Elmelhat, Ahmed	Comparison between Prophylactic versus Therapeutic Doses of Low-Molecular-Weight Heparin in Severely Ill Coronavirus Disease 2019 Patients in Relation to Disease Progression and Outcome	2020-10-26		.txt	text/plain	3189	158	49	INTRODUCTION: The predominant coagulation abnormalities in patients with coronavirus disease 2019 (COVID-19) suggest a hypercoagulable state and are consistent with uncontrolled clinical observations of an increased risk of venous thromboembolism. CONCLUSION: Our results showed that use of prophylactic dose of enoxaparin might have some benefits compared to the therapeutic dose in terms of less duration of ICU and hospital stay, duration of oxygen support, need and duration of MV, and normalization of inflammatory markers. There was a significant difference between both study groups in enoxaparin duration, time to ferritin and Ddimer improvement, and the duration of MV and O 2 support duration, with longer duration among group 2 cases (therapeutic dose) compared to group 1 (prophylactic dose) in all the above-mentioned variables. Our study compared the effect of different dose regimens of the anticoagulant enoxaparin (prophylactic and therapeutic) that was administered to patients with severe COVID-19 infection, and we compared the clinical outcome as well as improvement in laboratory parameters in both groups.	./cache/cord-035024-kx9jfssi.txt	./txt/cord-035024-kx9jfssi.txt